CancerTYPE ID (bioTheranostics Inc.)July 30, 2018
The identification of the primary site of cancer is the basis for prognosis and determination of appropriate treatment for patients with metastatic cancer. However, even with the vast available diagnostic tests and evaluations, a detailed investigation can still fail to identify the primary cancer site in a subset of patients. Recent advances in genomic profiling provide opportunities to characterize cancer of unknown primary (CUP) and offer insight into pathways and cellular systems with abnormalities that may help guide therapy. This report reviews the CancerTYPE ID test, which is intended to aid in the identification of the site of origin in cancers with indeterminate, uncertain, or differential diagnoses.
If you have a Hayes login, click here to view the full report on the Knowledge Center.